Does dulaglutide impact a composite outcome reflecting atherosclerosis? A post-hoc analysis of the REWIND trial
29 August 2022 (11:15 - 11:55)
Organised by:
Abstract
Slides
About the speaker
Karolinska Institute, Stockholm (Sweden)
5 More presentations in this session
Doctor N. Chew (Singapore, SG)
Doctor K. Olesen (Aarhus, DK)
Doctor J. Yeo (Leicester, GB)
Doctor L. Vassallo (Msida, MT)
Access the full session
The Event
ESC Congress 2022
29 August 2022
11:15 CET
